ResMed Inc. (LON:0KW4)
| Market Cap | 27.43B -2.1% |
| Revenue (ttm) | 4.01B +9.6% |
| Net Income | 1.10B +19.0% |
| EPS | 7.51 +19.4% |
| Shares Out | n/a |
| PE Ratio | 24.85 |
| Forward PE | 22.26 |
| Dividend | 1.72 (0.68%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 537 |
| Average Volume | 216 |
| Open | 270.00 |
| Previous Close | 256.57 |
| Day's Range | 245.26 - 277.00 |
| 52-Week Range | 199.71 - 297.98 |
| Beta | 0.88 |
| RSI | 48.55 |
| Earnings Date | Jan 29, 2026 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial numbers in USD Financial StatementsNews
TriaGen Wealth Management LLC Sells 7,758 Shares of ResMed Inc (RMD)
TriaGen Wealth Management LLC Sells 7,758 Shares of ResMed Inc (RMD)
Belpointe Asset Management LLC Sells 748 Shares of ResMed Inc (RMD)
Belpointe Asset Management LLC Sells 748 Shares of ResMed Inc (RMD)
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. See why RMD is a Strong Sell.
Bayforest Capital Ltd Sells 350 Shares of ResMed Inc (RMD)
Bayforest Capital Ltd Sells 350 Shares of ResMed Inc (RMD)
ResMed Inc. 2026 Q2 - Results - Earnings Call Presentation
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
On Thursday, ResMed Inc (NYSE: RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72 . Quarterly sales increased 11% year over year to $1.42 billion,...
Analysts Maintain Bull Case On ResMed Despite Competition Concerns
On Thursday, ResMed Inc (NYSE: RMD) reported that second-quarter fiscal 2026 adjusted earnings of 2.81, beating the consensus of $2.72.
RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News
RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | RMD Stock News
Wells Fargo Analyst Raises ResMed (RMD) Price Target to $270 | RMD Stock News
Friedenthal Financial Sells 3,869 Shares of ResMed Inc (RMD)
Friedenthal Financial Sells 3,869 Shares of ResMed Inc (RMD)
ResMed (RMD) Maintains Quarterly Dividend of $0.60 Per Share
ResMed (RMD) Maintains Quarterly Dividend of $0.60 Per Share
ResMed declares $0.60 dividend
ResMed (RMD) declares a $0.60 quarterly dividend (0.93% forward yield). Key dates: record/ex-div Feb 12; payable Mar 19.
ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
Q2 2026 Resmed Inc Earnings Call Transcript
Q2 2026 Resmed Inc Earnings Call Transcript
ResMed shares slip after Q2 FY26 results release
ResMed Inc (NYSE: RMD) shares closed at $257.41, down 0.12% on the day. The stock moved lower following the release of the company’s second-quarter fiscal 2026 financial results, which outlined quarte...
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments
ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript
ResMed (RMD) Q2 2026 Earnings Call Transcript
ResMed (RMD) Q2 2026 Earnings Call Transcript
ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...
Resmed (RMD) Surpasses Revenue Expectations in Q2
Resmed (RMD) Surpasses Revenue Expectations in Q2
ResMed beats quarterly profit estimates on strong demand for its sleep devices
Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.
Resmed Inc Q2 Profit Advances
(RTTNews) - Resmed Inc (RMD.AX) released earnings for its second quarter that Increases, from last year
ResMed Non-GAAP EPS of $2.81 beats by $0.09, revenue of $1.4B in-line
Earnings Breakdown: ResMed Q2
ResMed (NYSE: RMD) released its Q2 earnings on Thursday, January 29, 2026 at 04:05 PM. Here's what's important from the earnings announcement. Earnings ResMed beat estimated earnings by 4.0%, reporti...
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com